title: Establishing a pharmacy presence in the emergency department: opportunities and challenges in the French setting.
abstract: Overview of clinical pharmacy practice around the world shows that pharmaceutical services in emergency departments (EDs) are far less common in Europe than in North America. Reported experiences have shown the impact of a clinical pharmacy service on drug utilisation and safety issues. This commentary presents the implementation of a pharmacy presence in the ED of a French tertiary care hospital. Our experience helps to define the role of the clinical pharmacist in the ED, including patient interviewing, providing medication reconciliation, promoting drug safety, and supporting specific interventions to improve quality of care and patient safety. The role of ED pharmacists in the improvement of quality of care is not necessarily limited to drug therapy, e.g. by helping outpatients to access care and treatment facilities as best suits their needs. Challenges of implementing ED pharmacy services have been identified well, but still require developing strategies to be overcome.
authors.affiliation: Emergency Department, Teaching Hospital, Nantes, France, lucien.roulet@gmail.com.
authors.forename: Lucien
authors.initials: L
authors.lastname: Roulet
authors.forename: Nathalie
authors.initials: N
authors.lastname: Asseray
authors.forename: Françoise
authors.initials: F
authors.lastname: Ballereau
mesh_terms: D004636:Emergency Service, Hospital / Q000458:organization & administration*; D005602:France; D006801:Humans; D059065:Medication Reconciliation / Q000458:organization & administration; D061214:Patient Safety; D010607:Pharmacy Service, Hospital / Q000458:organization & administration*; D024382:Professional Role; D011787:Quality of Health Care / Q000458:organization & administration; D062606:Tertiary Care Centers / Q000458:organization & administration*
references.citation: Pharm World Sci. 2010 Feb;32(1):90-6
references.pmid: 19898991
references.citation: J Eval Clin Pract. 2011 Jun;17(3):478-85
references.pmid: 21040247
references.citation: Eur J Intern Med. 2011 Aug;22(4):382-5
references.pmid: 21767756
references.citation: Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):151-9
references.pmid: 23124864
references.citation: Can J Hosp Pharm. 2009 May;62(3):238-42
references.pmid: 22478896
references.citation: Am J Hosp Pharm. 1981 May;38(5):684-7
references.pmid: 7282697
references.citation: Therapie. 2012 Sep-Oct;67(5):447-55
references.pmid: 23241254
references.citation: Thromb Haemost. 2008 Oct;100(4):685-92
references.pmid: 18841293
references.citation: Am J Health Syst Pharm. 2009 Aug 15;66(16):1484-7
references.pmid: 19667006
references.citation: Therapie. 2011 Sep-Oct;66(5):421-9
references.pmid: 22031686
references.citation: Am J Hosp Pharm. 1977 Aug;34(8):843-6
references.pmid: 900137
references.citation: Am J Health Syst Pharm. 2009 Aug 1;66(15):1353-61
references.pmid: 19635771
references.citation: Am J Health Syst Pharm. 2005 Sep 1;62(17):1832-3
references.pmid: 16120745
references.citation: Emerg Med J. 2010 Dec;27(12):911-5
references.pmid: 20978003
references.citation: Ann Pharmacother. 1992 Apr;26(4):476-80
references.pmid: 1576381
references.citation: Am J Hosp Pharm. 1985 Apr;42(4):831-5
references.pmid: 4014234
references.citation: Presse Med. 2004 Jun 19;33(11):710-5
references.pmid: 15257227
references.citation: Am J Health Syst Pharm. 2007 Jan 1;64(1):63-8
references.pmid: 17189582
references.citation: Int J Clin Pharm. 2012 Dec;34(6):902-10
references.pmid: 22923368
references.citation: Am J Health Syst Pharm. 2010 Mar 1;67(5):375-9
references.pmid: 20172988